News
-
-
PRESS RELEASE
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum
Magdalena plans to file IND for new psychoactive drug in 2025 for mental health, focusing on ADHD and schizophrenia. Potential paradigm shift in plant-based drug development -
-
PRESS RELEASE
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications
Magdalena explores coca leaf's therapeutic benefits for ADHD and neuropsychiatric indications in partnership with Peru. Jaguar's Dr. King to present at Wisdom of the Leaf Coca Summit on coca-based Botanical Drugs -
-
PRESS RELEASE
Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder
Jaguar Health, Inc. initiates Phase 2 study for crofelemer, a novel plant-based drug, in pediatric MVID patients. Study aims to evaluate drug efficacy for rare diseases MVID and SBS-IF -
-
PRESS RELEASE
FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera
World Health Organization (WHO) elevates cholera to highest emergency level due to global resurgence. Crofelemer granted orphan-drug designation by FDA and EMA for cholera treatment -
-
PRESS RELEASE
Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer
Jaguar Health, Inc. announces virtual event on crofelemer clinical development efforts for rare diseases MVID and SBS-IF. CEO awarded 'Best CEO BioPharmaceuticals of the Year'
